Asthma is one of the most common chronic conditions of childhood and is associated with significant effect on quality of life. An ongoing controversy remains how to best treat asthma in children and adolescents. A provocative evolution in this controversy is the publication of new recommendations by the Global Initiative for Asthma (GINA), which present a significant change in asthma therapy.1 Step 1 recommendations for mild asthma in adolescents 12 years and older and adults changed from as-needed short-acting β-agonist (SABA) to as-needed low-dose inhaled corticosteroid (ICS) formoterol (a long-acting β-agonist [LABA]). In children aged 6 to 11 years, GINA recommends that ICS therapy be used with SABA as needed or regular ICS with as-needed SABA as an alternative approach.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Abrams EM, Becker AB, Szefler SJ. Paradigm Shift in Asthma Therapy for Adolescents: Should It Apply to Younger Children as Well? JAMA Pediatr. Published online January 06, 2020. doi:10.1001/jamapediatrics.2019.5214
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: